tbuckley/cabot-search huggingface dataset:
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
Authors: Harry L A Janssen, Jinlin Hou, Tarik Asselah, Henry L Y Chan, Fabien Zoulim, Yasuhito Tanaka, Ewa Janczewska, Ronald G Nahass, Stefan Bourgeois, Maria Buti, Pietro Lampertico, Oliver Lenz, Thierry Verbinnen, Joris Vandenbossche, Willem Talloen, Ronald Kalmeijer, Maria Beumont, Michael Biermer, Umesh Shukla
Journal: Gut (2023)

Objective We present the final analysis results of the phase 2 JADE study (ClinicalTrials.gov Identifier: NCT03361956 ). Design 232 patients with chronic hepatitis B (CHB) not currently treated at study start (NCT) at study start or virologically suppressed were randomised to receive 75 mg (part 1) or 250 mg (part 2) JNJ-56136379, a hepatitis B virus (HBV)–capsid assembly modulator, one time per day or placebo with nucleos(t)ide analogue (NA) (tenofovir disoproxil fumarate/entecavir) or JNJ-56136379 alone (NCT-only) for ≥24 and ≤48 weeks. Results In patients who are NCT hepatitis B e-antigen (HBeAg) positive, JNJ-56136379 75 mg+NA and 250 mg+NA showed limited mean (SE) hepatitis B surface antigen (HBsAg) declines (0.14 (0.10) and 0.41 (0.15), respectively) from baseline at Week 24 (primary endpoint; placebo+NA: 0.25 (0.11) log 10 international unit (IU)/mL). In patients who are NCT HBeAg positive, mean (SE) HBV DNA declines at Week 24 were 5.53 (0.23) and 5.88 (0.34) for JNJ-56136379 75 mg+NA and 250 mg+NA, respectively, versus 5.21 (0.42) log 10 IU/mL for placebo+NA. In NCT patients, mean (SE) HBV RNA declines were 2.96 (0.23) and 3.15 (0.33) versus 1.33 (0.32) log 10 copies/mL, respectively. Patients with HBsAg declines had HBeAg and hepatitis B core-related antigen (HBcrAg) declines and some early on-treatment isolated alanine aminotransferase flares. Viral breakthrough occurred with JNJ-56136379 monotherapy with the emerging resistant-variant T33N, but not with JNJ-56136379+NA. JNJ-56136379 treatment beyond Week 24 had a generally small additional effect on viral markers. No study treatment-related serious adverse events or clinically significant changes in laboratory parameters occurred. Conclusions In patients with non-cirrhotic CHB, JNJ-56136379+NA showed pronounced reductions in HBV DNA and HBV RNA, limited HBsAg or HBeAg declines in patients who are NCT HBeAg positive, and was well tolerated, but no clear benefit with regards to efficacy of JNJ-56136379 over NA was observed.
PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
Authors: Mengjie Zhao, Yanhui Li, Chenfei Lu, Fangshu Ding, Miao Xu, Xin Ge, Mengdie Li, Zhen Wang, Jianxing Yin, Junxia Zhang, Xiefeng Wang, Zehe Ge, Hong Xiao, Yong Xiao, Hongyi Liu, Wentao Liu, Yuandong Cao, Qianghu Wang, Yongping You, Xiuxing Wang, Kun Yang, Zhumei Shi, Xu Qian
Journal: Cancer Research (2023)

Radiotherapy is a major component of standard-of-care treatment for gliomas, the most prevalent type of brain tumor. However, resistance to radiotherapy remains a major concern. Identification of mechanisms governing radioresistance in gliomas could reveal improved therapeutic strategies for treating patients. Here, we report that mitochondrial metabolic pathways are suppressed in radioresistant gliomas through integrated analyses of transcriptomic data from glioma specimens and cell lines. Decreased expression of peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC1α), the key regulator of mitochondrial biogenesis and metabolism, correlated with glioma recurrence and predicted poor prognosis and response to radiotherapy of patients with glioma. The subpopulation of glioma cells with low-mitochondrial-mass exhibited reduced expression of PGC1α and enhanced resistance to radiotherapy treatment. Mechanistically, PGC1α was phosphorylated at serine (S) 636 by DNA-dependent protein kinase in response to irradiation. Phosphorylation at S636 promoted the degradation of PGC1α by facilitating its binding to the E3 ligase RNF34. Restoring PGC1α activity with expression of PGC1α S636A, a phosphorylation-resistant mutant, or a small-molecule PGC1α activator ZLN005 increased radiosensitivity of resistant glioma cells by reactivating mitochondria-related reactive oxygen species production and inducing apoptotic effects both in vitro and in vivo. In summary, this study identified a self-protective mechanism in glioma cells in which radiotherapy-induced degradation of PGC1α and suppression of mitochondrial biogenesis play a central role. Targeted activation of PGC1α could help improve response to radiotherapy in patients with glioma.Glioma cells reduce mitochondrial biogenesis by promoting PGC1α degradation to promote resistance to radiotherapy, indicating potential therapeutic strategies to enhance radiosensitivity.
TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
Authors: Lindsey J. Anstine, Parth R. Majmudar, Amy Aponte, Salendra Singh, Ran Zhao, Kristen L. Weber-Bonk, Fadi W. Abdul-Karim, Mitchell Valentine, Darcie D. Seachrist, Katelyn E. Grennel-Nickelson, Leslie Cuellar-Vite, Gina M. Sizemore, Steven T. Sizemore, Bryan M. Webb, Cheryl L. Thompson, Ruth A. Keri
Journal: Cancer Research (2023)

Abstract Breast cancer subtypes and their phenotypes parallel different stages of the mammary epithelial cell developmental hierarchy. Discovering mechanisms that control lineage identity could provide novel avenues for mitigating disease progression. Here we report that the transcriptional corepressor TLE3 is a guardian of luminal cell fate in breast cancer and operates independently of the estrogen receptor. In luminal breast cancer, TLE3 actively repressed the gene-expression signature associated with highly aggressive basal-like breast cancers (BLBC). Moreover, maintenance of the luminal lineage depended on the appropriate localization of TLE3 to its transcriptional targets, a process mediated by interactions with FOXA1. By repressing genes that drive BLBC phenotypes, including SOX9 and TGFβ2, TLE3 prevented the acquisition of a hybrid epithelial–mesenchymal state and reduced metastatic capacity and aggressive cellular behaviors. These results establish TLE3 as an essential transcriptional repressor that sustains the more differentiated and less metastatic nature of luminal breast cancers. Approaches to induce TLE3 expression could promote the acquisition of less aggressive, more treatable disease states to extend patient survival. Significance: Transcriptional corepressor TLE3 actively suppresses SOX9 and TGFβ transcriptional programs to sustain the luminal lineage identity of breast cancer cells and to inhibit metastatic progression.
The Integrative Studies on the Functional A-to-I RNA Editing Events in Human Cancers
Authors: Sijia Wu, Zhiwei Fan, Pora Kim, Liyu Huang, Xiaobo Zhou
Journal: Genomics Proteomics & Bioinformatics (2023)

Abstract Adenosine-to-inosine (A-to-I) RNA editing, constituting nearly 90% of all RNA editing events in humans, has been reported to contribute to the tumorigenesis in diverse cancers. However, the comprehensive map for functional A-to-I RNA editing events in cancers is still insufficient. To fill this gap, we systematically and intensively analyzed multiple tumorigenic mechanisms of A-to-I RNA editing events in samples across 33 cancer types from The Cancer Genome Atlas. For individual candidate among ∼ 1,500,000 quantified RNA editing events, we performed diverse types of downstream functional annotations. Finally, we identified 24,236 potentially functional A-to-I RNA editing events, including the cases in APOL1, IGFBP3, GRIA2, BLCAP, and miR-589-3p. These events might play crucial roles in the scenarios of tumorigenesis, due to their tumor-related editing frequencies or probable effects on altered expression profiles, protein functions, splicing patterns, and microRNA regulations of tumor genes. Our functional A-to-I RNA editing events (https://ccsm.uth.edu/CAeditome/) will help better understand the cancer pathology from the A-to-I RNA editing aspect.
Case-based similar image retrieval for weakly annotated large histopathological images of malignant lymphoma using deep metric learning
Authors: Noriaki Hashimoto, Yusuke Takagi, Hiroki Masuda, Hiroaki Miyoshi, Kei Kohno, Miharu Nagaishi, Kensaku Sato, Mai Takeuchi, Takuya Furuta, Keisuke Kawamoto, Kyohei Yamada, Mayuko Moritsubo, Kanako Inoue, Yasumasa Shimasaki, Yusuke Ogura, Teppei Imamoto, Tatsuzo Mishina, Ken Tanaka, Yoshino Kawaguchi, Shigeo Nakamura, Koichi Ohshima, Hidekata Hontani, Ichiro Takeuchi
Journal: Medical Image Analysis (2023)

In the present study, we propose a novel case-based similar image retrieval (SIR) method for hematoxylin and eosin (H&E) stained histopathological images of malignant lymphoma. When a whole slide image (WSI) is used as an input query, it is desirable to be able to retrieve similar cases by focusing on image patches in pathologically important regions such as tumor cells. To address this problem, we employ attention-based multiple instance learning, which enables us to focus on tumor-specific regions when the similarity between cases is computed. Moreover, we employ contrastive distance metric learning to incorporate immunohistochemical (IHC) staining patterns as useful supervised information for defining appropriate similarity between heterogeneous malignant lymphoma cases. In the experiment with 249 malignant lymphoma patients, we confirmed that the proposed method exhibited higher evaluation measures than the baseline case-based SIR methods. Furthermore, the subjective evaluation by pathologists revealed that our similarity measure using IHC staining patterns is appropriate for representing the similarity of H&E stained tissue images for malignant lymphoma.
Extracorporeal CPR in Out-of-Hospital Cardiac Arrest — Still on Life Support?
Authors: John F. Keaney, Thomas Münzel
Journal: New England Journal of Medicine (2023)

Despite many advances in the treatment of heart disease over the past four decades, up to one third of all patients with acute manifestations of heart disease do not reach the hospital after cardiac arrest. Only 8 to 10% of patients with out-of-hospital cardiac arrest survive; the event is responsible for up to 570,000 deaths annually in North America and Europe. The patients who are most likely to survive cardiac arrest are those who present with ventricular fibrillation that is responsive to defibrillation. Yet even among patients with a shockable rhythm, up to half will have ventricular fibrillation that is . . .
Antiretroviral Therapy and Adverse Pregnancy Outcomes in People Living with HIV
Authors: Ahizechukwu C. Eke, Mark Mirochnick, Shahin Lockman
Journal: New England Journal of Medicine (2023)

Use of antiretroviral therapy has led to a major decline in perinatal infections, but the regimen with the best safety profile is still not known. The literature on ART and pregnancy outcomes is reviewed.
Atopic Eruption of Pregnancy
Authors: Masakazu Kakurai, Kazumasa Oya
Journal: New England Journal of Medicine (2023)

A 37-year-old woman presented at 30 weeks’ gestation with a 4-month history of pruritic papules, nodules, and pustules on her trunk, arms, and legs. Biopsy revealed subepidermal pustules; stains for microorganisms were negative.
Presumed Nontraumatic Myositis Ossificans of the Extraocular Muscle
Authors: Lijuan Huang, Jingru Wang, Yingying Gao
Journal: Ophthalmology (2023)

Effective January 1, 2024, Pictures & Perspectives will publish online only, shared on the Academy's social media accounts, and highlighted in the next available Table of Contents. To learn more about submission requirements, visit our Guide for Authors at aaojournal.org. A 68-year-old woman had progressive left exotropia with restrictive adduction and mild pain for 10 years. She denied previous trauma or surgery. Computed tomography scan showed a 0.5 mm–length high-density lesion (A, arrow) at the attachment of the thickening lateral rectus muscle (A and B, ellipse), leading to a focal eminence of the retina (C, arrow). Surgical removal of the high-density lesion combined with the correction of exotropia was performed. Pathological examination demonstrated a mature bone nodule (D, × 200 magnification). Muscle biopsy revealed inflammatory cells, consistent with extraocular muscle myositis ossificans (Magnified version of Figure A-D is available online at www.aaojournal.org).
Reply to Chao Quan, Jinbo Chen, and Jiao Hu’s Letter to the Editor re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Follow-up Update of PURE-01 Trial. Clin Cancer Res 2022;28:5107–14
Authors: Giuseppe Basile, Marco Bandini, Francesco Montorsi, Andrea Necchi
Journal: European Urology (2023)
Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A
Authors: Annette von Drygalski, Pratima Chowdary, Roshni Kulkarni, Sophie Susen, Barbara A. Konkle, Johannes Oldenburg, Davide Matino, Robert Klamroth, Angela C. Weyand, Victor Jimenez-Yuste, Keiji Nogami, Stacey Poloskey, Bent Winding, Annemieke Willemze, Karin Knobe
Journal: New England Journal of Medicine (2023)

Efanesoctocog alfa provides high sustained factor VIII activity by overcoming the von Willebrand factor-imposed half-life ceiling. The efficacy, safety, and pharmacokinetics of efanesoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with severe hemophilia A are unclear.We conducted a phase 3 study involving patients 12 years of age or older with severe hemophilia A. In group A, patients received once-weekly prophylaxis with efanesoctocog alfa (50 IU per kilogram of body weight) for 52 weeks. In group B, patients received on-demand treatment with efanesoctocog alfa for 26 weeks, followed by once-weekly prophylaxis with efanesoctocog alfa for 26 weeks. The primary end point was the mean annualized bleeding rate in group A; the key secondary end point was an intrapatient comparison of the annualized bleeding rate during prophylaxis in group A with the rate during prestudy factor VIII prophylaxis. Additional end points included treatment of bleeding episodes, safety, pharmacokinetics, and changes in physical health, pain, and joint health.In group A (133 patients), the median annualized bleeding rate was 0 (interquartile range, 0 to 1.04), and the estimated mean annualized bleeding rate was 0.71 (95% confidence interval [CI], 0.52 to 0.97). The mean annualized bleeding rate decreased from 2.96 (95% CI, 2.00 to 4.37) to 0.69 (95% CI, 0.43 to 1.11), a finding that showed superiority over prestudy factor VIII prophylaxis (P<0.001). A total of 26 patients were enrolled in group B. In the overall population, nearly all bleeding episodes (97%) resolved with one injection of efanesoctocog alfa. Weekly prophylaxis with efanesoctocog alfa provided mean factor VIII activity of more than 40 IU per deciliter for the majority of the week and of 15 IU per deciliter at day 7. Prophylaxis with efanesoctocog alfa for 52 weeks (group A) improved physical health (P<0.001), pain intensity (P = 0.03), and joint health (P = 0.01). In the overall study population, efanesoctocog alfa had an acceptable side-effect profile, and the development of inhibitors to factor VIII was not detected.In patients with severe hemophilia A, once-weekly efanesoctocog alfa provided superior bleeding prevention to prestudy prophylaxis, normal to near-normal factor VIII activity, and improvements in physical health, pain, and joint health. (Funded by Sanofi and Sobi; XTEND-1 ClinicalTrials.gov number, NCT04161495.).
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
Authors: S.J. Luen, G. Viale, S. Nik-Zainal, P. Savas, R. Kammler, P. Dell’Orto, O. Biasi, A. Degasperi, L.C. Brown, I. Láng, G. MacGrogan, C. Tondini, M. Bellet, F. Villa, A. Bernardo, E. Ciruelos, P. Karlsson, P. Neven, M. Climent, B. Müller, W. Jochum, H. Bonnefoi, S. Martino, N.E. Davidson, C. Geyer, S.K. Chia, J.N. Ingle, R. Coleman, C. Solbach, B. Thürlimann, M. Colleoni, A.S. Coates, A. Goldhirsch, G.F. Fleming, P.A. Francis, T.P. Speed, M.M. Regan, S. Loi
Journal: Annals of Oncology (2023)
Early Extracorporeal CPR for Refractory Out-of-Hospital Cardiac Arrest
Authors: Martje M. Suverein, Thijs S.R. Delnoij, Roberto Lorusso, George J. Brandon Bravo Bruinsma, Luuk Otterspoor, Carlos V. Elzo Kraemer, Alexander P.J. Vlaar, Joris J. van der Heijden, Erik Scholten, Corstiaan den Uil, Tim Jansen, Bas van den Bogaard, Marijn Kuijpers, Ka Yan Lam, José M. Montero Cabezas, Antoine H.G. Driessen, Saskia Z.H. Rittersma, Bram G. Heijnen, Dinis Dos Reis Miranda, Gabe Bleeker, Jesse de Metz, Renicus S. Hermanides, Jorge Lopez Matta, Susanne Eberl, Dirk W. Donker, Robert J. van Thiel, Sakir Akin, Oene van Meer, José Henriques, Karen C. Bokhoven, Loes Mandigers, Jeroen J.H. Bunge, Martine E. Bol, Bjorn Winkens, Brigitte Essers, Patrick W. Weerwind, Jos G. Maessen, Marcel C.G. van de Poll
Journal: New England Journal of Medicine (2023)

Extracorporeal cardiopulmonary resuscitation (CPR) restores perfusion and oxygenation in a patient who does not have spontaneous circulation. The evidence with regard to the effect of extracorporeal CPR on survival with a favorable neurologic outcome in refractory out-of-hospital cardiac arrest is inconclusive.
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
Authors: Katia Alves, Joyce S Plested, Shirley Galbiati, Gordon Chau, Shane Cloney-Clark, Mingzhu Zhu, Raj Kalkeri, Nita Patel, Kathy Smith, Alex Marcheschi, Susan Pfeiffer, Heather McFall, Gale Smith, Gregory M Glenn, Filip Dubovsky, Raburn M Mallory
Journal: New England Journal of Medicine (2023)
Cystatin C–Based Equation to Estimate GFR without the Inclusion of Race and Sex
Authors: Hans Pottel, Jonas Björk, Andrew D Rule, Natalie Ebert, Björn O Eriksen, Laurence Dubourg, Emmanuelle Vidal-Petiot, Anders Grubb, Magnus Hansson, Edmund J Lamb, Karin Littmann, Christophe Mariat, Toralf Melsom, Elke Schaeffner, Per-Ola Sundin, Anna Åkesson, Anders Larsson, Etienne Cavalier, Justine B Bukabau, Ernest K Sumaili, Eric Yayo, Dagui Monnet, Martin Flamant, Ulf Nyman, Pierre Delanaye
Journal: New England Journal of Medicine (2023)

The accuracy of estimation of kidney function with the use of routine metabolic tests, such as measurement of the serum creatinine level, has been controversial. The European Kidney Function Consortium (EKFC) developed a creatinine-based equation (EKFC eGFRcr) to estimate the glomerular filtration rate (GFR) with a rescaled serum creatinine level (i.e., the serum creatinine level is divided by the median serum creatinine level among healthy persons to control for variation related to differences in age, sex, or race). Whether a cystatin C-based EKFC equation would increase the accuracy of estimated GFR is unknown. We used data from patients in Sweden to estimate the rescaling factor for the cystatin C level in adults. We then replaced rescaled serum creatinine in the EKFC eGFRcr equation with rescaled cystatin C, and we validated the resulting EKFC eGFRcys equation in cohorts of White patients and Black patients in Europe, the United States, and Africa, according to measured GFR, levels of serum creatinine and cystatin C, age, and sex. On the basis of data from 227,643 patients in Sweden, the rescaling factor for cystatin C was estimated at 0.83 for men and women younger than 50 years of age and 0.83 + 0.005 × (age - 50) for those 50 years of age or older. The EKFC eGFRcys equation was unbiased, had accuracy that was similar to that of the EKFC eGFRcr equation in both White patients and Black patients (11,231 patients from Europe, 1093 from the United States, and 508 from Africa), and was more accurate than the Chronic Kidney Disease Epidemiology Collaboration eGFRcys equation recommended by Kidney Disease: Improving Global Outcomes. The arithmetic mean of EKFC eGFRcr and EKFC eGFRcys further improved the accuracy of estimated GFR over estimates from either biomarker equation alone. The EKFC eGFRcys equation had the same mathematical form as the EKFC eGFRcr equation, but it had a scaling factor for cystatin C that did not differ according to race or sex. In cohorts from Europe, the United States, and Africa, this equation improved the accuracy of GFR assessment over that of commonly used equations. (Funded by the Swedish Research Council.).
A “Method of Use” to Prevent Generic and Biosimilar Market Entry
Authors: S. Sean Tu, Ameet Sarpatwari
Journal: New England Journal of Medicine (2023)

Interview with Dr. Ameet Sarpatwari on a legal case that could affect market entry of generic and biosimilar drugs. (12:14)Download A critical pathway that generics and biosimilars manufacturers have used to circumvent patent thickets has been "skinny labeling." But a recent court ruling has placed this pathway under threat.
Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
Authors: Jing Zou, Chaitanya Kurhade, Sohil Patel, Nicholas Kitchin, Kristin Tompkins, Mark Cutler, David Cooper, Qi Yang, Hui Cai, Alexander Muik, Ying Zhang, Dung-Yang Lee, Ugur Şahin, Annaliesa S Anderson, William C Gruber, Xuping Xie, Kena A Swanson, Pei-Yong Shi
Journal: New England Journal of Medicine (2023)
Mast cell–mediated inflammation relies on insulin-regulated aminopeptidase controlling cytokine export from the Golgi
Authors: Mirjana Weimershaus, Caroline Carvalho, Rachel Rignault, Emmanuelle Waeckel-Enee, Michael Dussiot, Peter van Endert, Thiago Trovati Maciel, Olivier Hermine
Journal: Journal of Allergy and Clinical Immunology (2023)

On activation, mast cells rapidly release preformed inflammatory mediators from large cytoplasmic granules via regulated exocytosis. This acute degranulation is followed by a late activation phase involving synthesis and secretion of cytokines, growth factors, and other inflammatory molecules via the constitutive pathway that remains ill defined.We investigated the role for an insulin-responsive vesicle-like endosomal compartment, marked by insulin-regulated aminopeptidase (IRAP), in the secretion of TNF-α and IL-6 in mast cells and macrophages.Murine knockout (KO) mouse models (IRAP-KO and kit-Wsh/sh) were used to study inflammatory disease models and to measure and mechanistically investigate cytokine secretion and degranulation in bone marrow-derived mast cells in vitro.IRAP-KO mice are protected from TNF-α-dependent kidney injury and inflammatory arthritis. In the absence of IRAP, TNF-α and IL-6 but not IL-10 fail to be efficiently secreted. Moreover, chemical targeting of IRAP endosomes reduced proinflammatory cytokine secretion. Mechanistically, impaired TNF-α export from the Golgi and reduced colocalization of vesicle-associated membrane protein (VAMP) 3-positive TNF-α transport vesicles with syntaxin 4 (aka Stx4) was observed in IRAP-KO mast cells, while VAMP8-dependent exocytosis of secretory granules was facilitated.IRAP plays a novel role in mast cell-mediated inflammation through the regulation of exocytic trafficking of cytokines.
Assessing the effectiveness of COVID-19 vaccines in Pakistan: A test-negative case-control study
Authors: Muhammad Imran Nisar, Nadia Ansari, Amyn Abdul Malik, Shahira Shahid, Kiran Ramzan Ali Lalani, Maaheen Ahmed Chandna, Ayesha Mansoor Younus, Zahra Hasan, Unab Khan, Farah Khalid, Marvi Mahesar, Muhammad Farrukh Qazi, Inci Yildirim, Fyezah Jehan, Saad Bin Omer
Journal: Journal of Infection (2023)
Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms
Authors: Amelie Jaeger, Sudheer Madan Mohan Gambheer, Xiaoyang Sun, Dmitry Chernyakov, Oleksandra Skorobohatko, Thomas M. Mack, Sandra Kissel, Dietmar Pfeifer, Robert Zeiser, Paul Fisch, Geoffroy Andrieux, Daniela Bräuer-Hartmann, Marcus Bauer, Susann Schulze, Marie Follo, Melanie Boerries, Nikolas von Bubnoff, Cornelius Miething, Jose Villacorta Hidalgo, Claudius Klein, Thomas Weber, Claudia Wickenhauser, Mascha Binder, Christine Dierks
Journal: Blood (2023)